Red Label
Red Label
Current Events Tariff Risk

Trump Tariffs: What Mid-Market PE Needs to Know Now

Your portfolio's China exposure is 3.8x higher than you think. Here's what the data shows and what questions to ask.

Red Label Intelligence
37%
Effective China tariff rate
3.8x
Hidden exposure multiplier
2%
Companies with full supply chain visibility
$1T
PE exit backlog

The Diagnostic

Most PE firms think they understand their tariff exposure. They don't.

Brookings research shows that "look-through" analysis (tracing inputs through Tier 2 and Tier 3 suppliers) reveals China dependence that's 3.8 times higher than face-value measurements. Meanwhile, only 2% of companies have full visibility into their extended supplier networks, per McKinsey.

The implication for due diligence is clear: asking "what's your China exposure?" isn't enough. The real question is: what's your suppliers' China exposure?

Current Tariff Rates (January 2026)

Country Base Rate Steel/Aluminum Exemptions Legal Status
China 20% (10% IEEPA + 10% reciprocal) 50% 178 product exclusions SCOTUS Review
Canada 35% 50% USMCA goods exempt (~87%) SCOTUS Review
Mexico 25% 50% USMCA goods exempt (~84%) SCOTUS Review
EU 15% cap 50% Aug 2025 framework Stable
UK 10% 50% May 2025 deal Stable
Rest of World 10% 50% Varies by deal Baseline
Source: USTR, Congressional Research Service, Federal Register. IEEPA tariffs under Supreme Court review; decision expected Q1 2026.

The Hidden Exposure Problem

What Companies Report vs. Reality

Vuzix Corporation reports only 2.1% direct China revenue. No Chinese customers or suppliers on paper. But their DLP display technology comes from Texas Instruments, which sources silicon wafers, rare earth elements, and semiconductor materials from China.

This pattern repeats across portfolios. Face-value exposure understates true risk by nearly 4x.

Sector Vulnerability

Rare Earth Refining 85-90%
Consumer Electronics 65%
Automotive Tooling 60-70%
Solar PV Modules 53%
Pharma APIs (by volume) 40%
Source: Rhodium Group, China Briefing

The "China+1" Illusion

"Diversified to Vietnam" or "nearshored to Mexico" doesn't mean China-free. Chinese FDI is surging in both countries, and products assembled there often contain Chinese components.

Vietnam

  • $4.73B: Chinese FDI in 2024
  • 955: New Chinese projects (28% of all foreign projects)
  • 65%: Vietnamese FDI workforce in low-value assembly
  • $123.5B: Vietnam's trade surplus with US (3rd largest)

Mexico

  • ~$15B: Estimated PRC-linked investment (vs. $2B official)
  • 60%: YoY increase in Chinese container arrivals (Q1 2024)
  • $5.3B: Auto parts imports from China (up from $2B in 2013)
  • 11: Anti-dumping probes vs. China in 2025

Nomura analysis: adjusting for circumvention, China's direct + indirect share of US imports fell only from 20.6% (2017) to 18.5% (2023), far less than face-value data suggests.

Portfolio Impact Assessment

Partners Group
1-3%
Estimated aggregate EBITDA decrease (NAV-weighted, 75+ assets reviewed)
NB Private Equity
86%
Of portfolio expects little to no direct impact
Deal Market
-24%
Deal value drop in April 2025 vs. Q1

The Caveat

These assessments focus on direct exposure. As Alvarez & Marsal notes: "While most fund managers understand their direct tariff exposure, fewer have drilled into the potential impact of secondary suppliers. What you don't know is the inflationary exposure...when your supplier now passes on a 25% increase."

Due Diligence Questions That Matter

Based on William Blair's tariff DD framework and our analysis:

Supply Chain

  • Where do your Tier 2 and Tier 3 suppliers have production sites?
  • What percentage of critical components are single-sourced from China or China-proxy locations?
  • For "Vietnam-sourced" or "Mexico-sourced" inputs, what's the actual country of origin for sub-components?

Financial Impact

  • What's gross margin sensitivity to 10-25% input cost increases?
  • Can the company pass costs to customers without losing share?
  • What's the timeline and capex for supplier diversification?

What to Watch

Event Timeline Implication
Supreme Court IEEPA decision Q1 2026 Could invalidate majority of tariffs; $200B+ refund potential
USMCA review begins July 2026 Current exemptions (~85% of Canada/Mexico trade) at risk
US-China arrangement expires Nov 2026 10% reciprocal rate freeze ends; could escalate to 34%+

The Bottom Line

Standard tariff exposure analysis understates true risk by nearly 4x. Mid-market PE firms should assume their portfolios have more China exposure than reported, and due diligence should focus on Tier 2/3 suppliers, not just direct sourcing.

The firms asking "what's your China exposure?" are asking the wrong question. The right question: "what's your suppliers' China exposure?"

Data Sources

Source Data Date
Brookings Institution 3.8x hidden exposure multiplier 2024
USTR Official tariff rates and exclusions 2025
Congressional Research Service Presidential tariff actions timeline 2025
Rhodium Group China supply chain analysis, sector exposure 2024
McKinsey 2% supply chain visibility statistic 2024
PwC PE tariff impact analysis 2025
William Blair DD question framework 2025
Nomura Circumvention analysis 2024